Skip to content
Peptide Atlas
All peptides

Palmitoyl Tetrapeptide-7

Tier 3 · Reported use
Also known as Pal-GQPR · Palmitoyl tetrapeptide-3

The strongest evidence present is a small (N=17), 1-month observational human cosmetic study of standalone Pal-GQPR (src-7), plus human data on the Matrixyl 3000 blend. However, most mechanistic support is in vitro (IL-6/IL-1β suppression in keratinocytes and fibroblasts) or proprietary expert opinion from the manufacturer (Sederma). Notably, several sources state Pal-GQPR has never been tested alone in a controlled human clinical trial, and essentially all robust positive results derive from the two-peptide Matrixyl 3000 blend containing Pal-GHK. Human evidence is therefore limited, small, and observational.

Half-life
Not recorded
Routes
Topical
Goals
Skin anti-aging · Anti-inflammatory / inflammaging · Skin barrier and structural integrity · Antipollution skincare
Cost / mg
Not recorded

How it works

Palmitoyl tetrapeptide-7 is a lab-made peptide (the four amino acids Gly-Gln-Pro-Arg) attached to a fatty acid (palmitic acid). The fatty tail makes it more oil-loving so it can penetrate the skin's outer barrier and reach the deeper dermis. Its main reported action is calming chronic, low-grade inflammation in the skin by lowering the signaling molecule IL-6, which tends to rise with age and after UV exposure. By reducing this inflammatory signal, it is thought to help protect the skin's structural support (extracellular matrix) from breaking down. It is used almost exclusively as a topical anti-aging/skin-conditioning cosmetic ingredient, most famously as one of the two active peptides in the Matrixyl 3000 blend.

Overview

Overview

Palmitoyl Tetrapeptide-7 (also known as Pal-GQPR or Palmitoyl tetrapeptide-3) is a synthetic lipopeptide used almost exclusively as a topical cosmetic ingredient. It consists of the tetrapeptide Gly-Gln-Pro-Arg (GQPR) conjugated to palmitic acid (a 16-carbon fatty acid) at its N-terminus. The GQPR sequence is derived from residues 224–227 of immunoglobulin G (IgG), a domain associated with modulating immune responses.

The palmitoyl modification increases the peptide's lipophilicity, improving penetration through the stratum corneum to reach the dermis, and reduces the rate of proteolytic cleavage relative to the unmodified peptide. Applied topically (cream, gel, or lotion), it acts mainly locally in the skin, with little reaching the bloodstream.

Origin and Use

The ingredient was originally developed by Sederma SAS (around 2005) under the trade name Rigin, as an anti-inflammatory cosmeceutical targeting inflammaging. It functions primarily as a skin-conditioning agent in cosmetics. It is best known as one of the two active components of Matrixyl 3000, combined with palmitoyl tripeptide-1 (Pal-GHK) — in that blend, Pal-GQPR is described as suppressing the inflammatory environment driving matrix degradation while Pal-GHK stimulates collagen synthesis. As of 2018 it was reported to be the most frequently used peptide ingredient in anti-aging cosmetic products globally.

Reported Mechanism

The peptide's principal documented action is suppression of IL-6 secretion in keratinocytes and fibroblasts, addressing the chronic low-grade inflammation that accelerates skin aging. In vitro:

  • Basal (constitutive) IL-6 secretion was reduced by up to ~40%.
  • In UV-exposed cells, IL-6 was reduced by ~86% versus untreated UV-exposed controls (cell culture only, not demonstrated in human skin).
  • Anti-inflammatory activity was reported comparable to DHEA (in vitro UV-cytokine reduction ~37% vs ~34%).

The peptide is designed to mimic DHEA activity and restore cytokine balance in mature skin, since DHEA declines with age and is associated with rising IL-6. By lowering IL-6, it is proposed to protect extracellular matrix components (with IL-6 suppression and MMP-1 inhibition as validated targets in skin-aging research). Additional expert/single-source claims include modulation of inflammaging and senescence-associated secretory phenotype, stimulation of laminin and nidogen at the dermal-epidermal junction, and stimulation of phagocytosis similar to Tuftsin. A PT-7 gel was also reported to reduce IL-1β and IL-6 induced by PM10 particulate-matter exposure, positioning it as a potential antipollution ingredient.

Clinical and Human Data

A standalone human study (N=17, 15 ppm, 1 month) reported a face firmness increase of 19%, neck firmness increase of 40%, elasticity improvement of 17% (face) and 27% (neck), deepest-wrinkle reduction of 56% at 15 days, and roughness reduction of 14%. The Matrixyl 3000 blend (Pal-GQPR + Pal-GHK) has been reported to exhibit noticeable anti-aging effects and to improve skin appearance and elasticity. Nanoliposomal co-delivery has been explored to enhance the bioactivity of anti-aging peptides in skin.

Chemistry

Reported molecular formula C34H62N8O7, molecular weight approximately 694.9 Da, CAS 221227-05-0, FDA UNII Q41S464P1R. (Note: sources disagree on the reported molecular weight, and one source uses a conflicting sequence designation — see caveats.)

What the research shows

81 findings extracted from the 15 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 2 human study findings, 3 in vitro findings and 8 expert opinion findings.

  • human studyA standalone study reported improvements in skin firmness and wrinkle reduction4

  • human studyA standalone study (N=17, 15 ppm, 1 month) reported face firmness increase of 19%, neck firmness increase of 40%, elasticity improvement of 17% (face) and 27% (neck), deepest wrinkle reduction of 56% at 15 days, and roughness reduction of 14%4

  • in vitroPT-7 gel reduced the IL-1β and IL-6 expression levels caused by PM10 exposure2

  • in vitroAnti-aging peptides including palmitoyl tetrapeptide-7 can improve skin appearance and elasticity3

  • in vitroCells exposed to UV radiation and treated with Pal-GQPR showed an 86% reduction in IL-6 levels compared to UV-exposed untreated cells11

  • expert opinionThis ingredient has never been tested alone in a human clinical trial10

  • expert opinionEvery positive result comes from Matrixyl 3000 — a two-peptide blend that also contains Pal-GHK, a collagen-stimulating peptide with stronger independent biology10

  • expert opinionWhether Pal-GQPR contributes meaningfully to that combination, or whether it is a supporting actor overshadowed by a better-studied partner, remains entirely unknown10

Show the remaining 5

  • expert opinionPal-GQPR has never been tested alone in a human trial10

  • expert opinionThe in vitro mechanism work is almost entirely proprietary (Sederma, the manufacturer)10

  • expert opinionIndependent peer-reviewed validation of GQPR's specific targets and binding behavior is minimal10

  • expert opinionIn the Matrixyl 3000 combination, Pal-GHK whose underlying biology (GHK matrikine signaling) is well-characterized across multiple labs may be doing most of the work10

  • expert opinionPalmitoyl Tetrapeptide-7 combined with Palmitoyl Tripeptide-1 in Matrixyl 3000 exhibits noticeable anti-aging effects12

How it works

Based on 10 in vitro findings, 23 expert opinion findings and 2 theoretical findings.

  • in vitroNanodelivery systems can increase the safety and bioactivity of anti-aging peptides3

  • in vitroPal-GQPR suppresses the inflammatory signalling molecule IL-6, which increases in skin with age and UV exposure and contributes to collagen breakdown4

  • in vitroIn vitro studies report up to 86% suppression of UV-induced IL-6 production4

  • in vitroLaboratory studies show suppression of IL-6 in UV-exposed cells, but this has only been demonstrated in cell cultures, not in human skin4

  • in vitroPal-GQPR suppresses IL-6 production by up to 40% under basal conditions and 86% under UV-induced stress conditions4

  • in vitroThe anti-inflammatory mechanism mimics aspects of DHEA activity, with in vitro comparisons showing comparable UV-cytokine reduction (37% versus 34%)4

  • in vitroIn lab dishes, it reduces the inflammatory signals especially IL-6 that UV exposure and aging trigger in skin cells10

  • in vitroPalmitoyl tetrapeptide-7 directly suppresses IL-6 secretion from both keratinocytes and fibroblasts11

Show the remaining 27

  • in vitroIn vitro studies demonstrated cells treated with Pal-GQPR showed reduced constitutive IL-6 secretion compared to untreated controls11

  • in vitroThe anti-inflammatory activity of Pal-GQPR was comparable to that of dehydroepiandrosterone (DHEA)11

  • expert opinionSusceptible to enzymatic degradation; palmitoyl anchor reduces proteolytic cleavage rate compared to unmodified peptide7

  • expert opinionDirectly reduces IL-6 secretion in keratinocytes and fibroblasts, addressing the chronic inflammation that accelerates skin aging7

  • expert opinionModulates inflammaging pathways and senescence-associated secretory phenotype to slow age-related skin deterioration at the cellular level7

  • expert opinionStimulates laminin and nidogen production at the dermal-epidermal junction, strengthening structural integrity and barrier resilience7

  • expert opinionPalmitoyl tetrapeptide-7 has peptide sequence Gly-Gln-Pro-Arg (GQPR)9

  • expert opinionThe Val-Gly-Val-Ala-Pro-Gly sequence is an elastin peptide9

  • expert opinionThe Gly-His-Lys sequence is a liver growth factor peptide and a fragment of type I collagen9

  • expert opinionThe sequence GQPR is borrowed from immunoglobulin proteins that help regulate your immune system10

  • expert opinionPalmitoyl Tetrapeptide-7 is the peacekeeper designed to suppress the chronic low-grade inflammation that degrades collagen faster than new collagen can replace it10

  • expert opinionBoth peptides are palmitoylated — conjugated to a fatty acid tail — for improved penetration through the skin's oily barrier10

  • expert opinionIL-6 suppression and MMP-1 inhibition are validated targets in skin aging research10

  • expert opinionThe GQPR sequence draws from immunoglobulin-like domains known to modulate immune responses10

  • expert opinionPalmitoyl tetrapeptide-7 (Pal-GQPR) is a synthetic lipopeptide consisting of the tetrapeptide Gly-Gln-Pro-Arg conjugated to palmitic acid at its N-terminus11

  • expert opinionThe GQPR sequence is derived from residues 224-227 of immunoglobulin G (IgG)11

  • expert opinionThe palmitoyl modification increases the peptide's lipophilicity, improving penetration through the stratum corneum barrier to reach the dermis11

  • expert opinionPal-GQPR suppresses the inflammatory environment that drives matrix degradation, while Pal-GHK stimulates collagen synthesis11

  • expert opinionPalmitoyl Tetrapeptide-7 is a lipopeptide designed to mimic DHEA activity and restore cytokine balance to mature skin12

  • expert opinionDHEA levels decrease with aging, leading to increased interleukin-6 levels12

  • expert opinionPalmitoyl Tetrapeptide-7 reduces basal and UV-induced secretions of interleukin-6 in keratinocytes and fibroblasts12

  • expert opinionPalmitoyl Tetrapeptide-7 stimulates phagocytosis similar to Tuftsin12

  • expert opinionReduction of IL-6 by Palmitoyl Tetrapeptide-7 protects extracellular matrix components from degradation12

  • expert opinionPalmitoyl oligopeptides are related structurally by an identical fatty, hydrophobic tail connected to a variable sequence of peptides13

  • expert opinionSome small peptides are potent stimulators of angiogenesis13

  • theoreticalPeptides have considerable difficulty penetrating the stratum corneum due to high molecular weight, hydrophilic character, and susceptibility to enzymatic degradation3

  • theoreticalPalmitoyl Tetrapeptide-7 has sequence Pal-GQPR (Pal-Gly-Gln-Pro-Arg), a fragment of immunoglobulin G (sequence 224-227)12

Dosing

Based on 5 expert opinion findings.

  • expert opinionTypical use concentrations of Palmitoyl Tetrapeptide-7 and related ingredients are <10 ppm1

  • expert opinionCustomary leave-on cosmetic use is below 10 ppm of the active peptide7

  • expert opinionIn manufacturer clinical testing the trade-solution blend was applied twice daily for about two months7

  • expert opinionApply Palmitoyl Tetrapeptide-7 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption7

  • expert opinionTypical use concentrations of these ingredients are < 10 ppm9

How the body handles it

Based on 2 expert opinion findings.

  • expert opinionEnhanced topical penetration via palmitoyl lipid modification enabling membrane interaction and dermal delivery7

  • expert opinionActs mainly at the skin; little reaches the bloodstream7

Safety and side effects

Based on 1 animal finding, 2 in vitro findings and 6 expert opinion findings.

  • animalcosmetic composition is safe in both in vitro and in vivo studies5

  • in vitroPT-7 gel demonstrated safety2

  • in vitrocosmetic composition is stable5

  • expert opinionLow use concentrations and negative safety test data reviewed obviate any concerns relating to the safety of Palmitoyl Tetrapeptide-7 in cosmetic products1

  • expert opinionPalmitoyl Tetrapeptide-7 is safe for use in cosmetic concentrations, typically ranging from 0.001% to 0.01% in finished products8

  • expert opinionLow use concentrations and negative safety test data reviewed obviate any concerns relating to the safety of these ingredients in cosmetic products9

  • expert opinionThese ingredients are safe in the present practices of use and concentration in cosmetics9

  • expert opinionPalmitoyl tetrapeptide-7 is safe in the present practices of use and concentration13

Show the remaining 1

  • expert opinionPalmitoyl oligopeptides data included chemistry (UV-visible spectral analysis, logP, and impurities data), methods of production, use concentration data, acute oral toxicity, ocular irritation, skin irritation/sensitization (animal and human), and genotoxicity13

What people use it for

Based on 3 in vitro findings, 9 expert opinion findings and 2 theoretical findings.

  • in vitroPT-7 is a promising antipollution cosmetic ingredient2

  • in vitroPalmitoyl tetrapeptide-7 (pal-KVK) can be co-delivered via nanoliposomes for anti-aging effects in skin3

  • in vitrocosmetic composition possesses preservative properties5

  • expert opinionPalmitoyl Tetrapeptide-7 functions primarily as a skin conditioning agent in cosmetics1

  • expert opinionApplied onto the skin as a cream, gel, or lotion — it works mainly where you put it7

  • expert opinionPal-GQPR is almost always used as a co-active alongside Pal-GHK in the Matrixyl 3000 blend rather than on its own7

  • expert opinionTripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 function primarily as skin conditioning agents9

  • expert opinionPalmitoyl Tetrapeptide-7 is a small peptide designed to calm inflammation in aging skin10

Show the remaining 6

  • expert opinionOriginally developed by Sederma SAS under the trade name Rigin as an anti-inflammatory cosmeceutical ingredient targeting inflammaging11

  • expert opinionPalmitoyl tetrapeptide-7 is one of the two active components of Matrixyl 3000, combined with palmitoyl tripeptide-111

  • expert opinionAs of 2018, palmitoyl tetrapeptide-7 was the most frequently used peptide ingredient in anti-aging cosmetic products globally11

  • expert opinionPalmitoyl Tetrapeptide-7 improves natural defence mechanisms, clearing cellular debris, and removing alien compounds12

  • theoreticalPalmitoyl Tetrapeptide-7 is designed to reduce skin inflammation and targets inflammatory signalling that contributes to skin ageing4

  • theoreticalIt is the anti-inflammatory component of the Matrixyl 3000 combination4

Other findings

Based on 1 expert opinion finding and 2 theoretical findings.

  • expert opinionMolecular weight of approximately 594.78 g/mol11

  • theoreticalPalmitoyl Tetrapeptide-7 has molecular weight approximately 694.9 Da (CAS 221227-05-0)4

  • theoreticalIt is a 4-amino acid lipopeptide with the sequence Pal-Gly-Gln-Pro-Arg4

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Sources disagree on the peptide's reported molecular weight

For the same compound (CAS 221227-05-0, sequence Pal-Gly-Gln-Pro-Arg), the reported molecular weight varies across references: ~694.9 Da (Palmitoyl Tetrapeptide-7 Dosing, Need to Know… | Peptide Initiative; Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin) | PeptideTrace), ~594.78 g/mol (Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin): Research Evidence & Safety Profile | PeptideInsight), and ~687 Da (Palmitoyl Tetrapeptide-7: Evidence & Research | Peptidings). These are genuinely different figures for the same molecule.

Limited evidence

Mechanistic data is largely proprietary and in vitro, not confirmed in human skin

Palmitoyl Tetrapeptide-7: Evidence & Research | Peptidings notes the in vitro mechanism work is almost entirely proprietary (Sederma, the manufacturer) and independent peer-reviewed validation of GQPR's specific targets and binding behavior is minimal. Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin) | PeptideTrace — PeptideTrace emphasizes IL-6 suppression has only been demonstrated in cell cultures, not in human skin.

Limited evidence

Standalone efficacy study is small, brief, and observational

The only cited standalone efficacy study (Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin) | PeptideTrace — PeptideTrace) had N=17 subjects, ran for 1 month at 15 ppm, and is an observational cosmetic study rather than a controlled trial, limiting the strength of the firmness, elasticity, and wrinkle-reduction figures.

Single source

Claims about laminin/nidogen stimulation and inflammaging modulation come from a single source

The specific claims that Pal-GQPR stimulates laminin and nidogen production at the dermal-epidermal junction and modulates senescence-associated secretory phenotype are reported only by Palmitoyl Tetrapeptide-7 Dosing, Need to Know… | Peptide Initiative and are not corroborated by other sources.

Using it with other compounds

Check a stack
  • Palmitoyl Tripeptide-1Complementary

    May be complementary

    These two are the classic 'Matrixyl 3000' pairing in cosmetic formulations. Palmitoyl Tripeptide-1 (Pal-GHK) is a matrikine that actively drives fibroblasts to build new collagen, elastin and glycosaminoglycans, while Palmitoyl Tetrapeptide-7 works from the other direction — calming inflammatory cytokines (IL-6, IL-1β) and protecting the existing matrix from MMP-driven breakdown. Building plus protecting is exactly the kind of different-mechanism convergence that makes them a well-established, synergistic skin-firmness combination.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    The mechanisms clearly justify this complementary relationship. Peptide B (Pal-GHK) actively stimulates collagen, elastin, and GAG synthesis via TGF-β and matrikine signaling pathways, while Peptide A (Pal-Tetrapeptide-7) suppresses IL-6 and IL-1β cytokine signaling and inhibits MMP-1-mediated matrix degradation. Both peptides share documented anti-inflammatory and dermal_matrix tags, and their mechanisms operate through distinct pathways that converge on matrix preservation and improvement: one through anabolic synthesis, the other through catabolic suppression and inflammation reduction. This represents genuine mechanistic complementarity rather than redundancy, supporting the proposed relationship and explanation.

    Timing Topical; apply together in the same routine.

    Shares dermal matrix · anti inflammatory

  • KPVComplementary

    No documented conflict

    Both reduce skin inflammation but at different points: palmitoyl tetrapeptide-7 suppresses IL-6/IL-1β in keratinocytes and fibroblasts, while KPV reduces keratinocyte apoptosis and inflammation (including from particulate matter) via NF-κB. In a topical anti-inflammaging context they address overlapping but distinct inflammatory signals.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly demonstrate anti-inflammatory activity in skin cells. KPV suppresses TNF-alpha, IL-1beta, IL-6, and COX-2 via NF-κB pathway inhibition in keratinocytes. Palmitoyl tetrapeptide-7 reduces IL-6 and IL-1β secretion in keratinocytes and fibroblasts. The proposed relationship correctly identifies that they target overlapping inflammatory cytokines (IL-6, IL-1β) but through distinct mechanisms—KPV via NF-κB/MAPK signaling and palmitoyl tetrapeptide-7 via direct IL-6/IL-1β cytokine pathway suppression. Both are tagged anti_inflammatory in their approved tags. The explanation accurately reflects the mechanistic material: they address the same inflammatory outcome (reduced skin inflammation) through complementary but different signaling pathways, making 'complementary' an appropriate relationship type supported by the provided mechanisms.

    Shares anti inflammatory

  • Alpha-MSHComplementary

    No documented conflict

    Alpha-MSH is anti-inflammatory in skin via NF-κB suppression (IκBα preservation), and Palmitoyl Tetrapeptide-7 achieves an overlapping outcome by lowering IL-6/IL-1β secretion. They converge on reduced cutaneous inflammation through different mechanisms; note that alpha-MSH also strongly drives pigmentation, which the tetrapeptide does not, so effects beyond inflammation are not shared.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides are documented as anti-inflammatory agents with distinct mechanistic pathways that converge on reducing skin inflammation. Alpha-MSH suppresses NF-κB signaling (IκBα preservation), while Palmitoyl Tetrapeptide-7 suppresses IL-6 and IL-1β cytokine signaling and modulates SASP. These are complementary approaches to the same outcome (reduced cutaneous inflammation) via different molecular routes. The explanation correctly acknowledges that Alpha-MSH has additional effects (melanin synthesis, pigmentation) not shared by the tetrapeptide, appropriately limiting the shared dimension claim to anti-inflammatory activity. The proposed relationship is well-justified by the provided mechanism material.

    Shares anti inflammatory

  • ElafinComplementary

    No documented conflict

    Both protect the extracellular matrix and dampen inflammation, but by non-overlapping mechanisms — Elafin blocks destructive serine proteases (elastase, proteinase 3) and modulates NF-κB, whereas Palmitoyl Tetrapeptide-7 suppresses IL-6/IL-1β and inhibits MMP-1-driven collagen breakdown. Together they cover a broader range of matrix-degrading enzymes and inflammatory drivers.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the proposed complementary relationship on the shared dimensions of dermal_matrix and anti_inflammatory. Palmitoyl Tetrapeptide-7 protects ECM via IL-6/IL-1β suppression and MMP-1 inhibition, while Elafin protects ECM via serine protease inhibition (elastase, proteinase 3) and NF-κB modulation. These are mechanistically distinct pathways targeting different classes of matrix-degrading enzymes and inflammatory mediators. The explanation accurately reflects the non-overlapping mechanisms described in both peptides' material, making them genuinely complementary rather than redundant.

    Shares dermal matrix · anti inflammatory

  • MatrixylComplementary

    May be complementary

    These two work as a classic cosmetic pair: Matrixyl actively builds new collagen and matrix, while Palmitoyl Tetrapeptide-7 calms inflammatory cytokines (IL-6, IL-1β) and protects the existing matrix from MMP-driven breakdown. One adds new material, the other prevents its degradation, so combining them addresses both sides of the collagen balance in aging skin.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the proposed complementary relationship on the dermal_matrix dimension. Matrixyl's mechanism explicitly stimulates collagen and extracellular matrix synthesis (types I, III, IV, fibronectin, GAGs) via matrikine and TGF-beta signaling, while also inhibiting MMPs and plasmin. Palmitoyl Tetrapeptide-7's mechanism reduces inflammatory cytokines (IL-6, IL-1β) that drive matrix degradation, inhibits MMP-1, and protects extracellular matrix from degradation. The proposed explanation accurately reflects both mechanisms: one actively builds matrix components while the other suppresses inflammatory drivers of matrix breakdown and prevents MMP-mediated degradation. This represents a genuine complementary pairing on the shared dermal_matrix dimension—anabolic versus catabolic balance—supported by the provided mechanism descriptions.

    Timing Topical use — designed to be co-formulated and applied together.

    Shares dermal matrix

  • LeuphasylComplementary

    No documented conflict

    Both are topical cosmetic peptides that improve skin appearance through different routes: Leuphasyl relaxes expression-line muscle signaling (and has reported minor matrix effects), while Palmitoyl Tetrapeptide-7 targets dermal-matrix protection and inflammation. Combining a wrinkle-relaxant with a matrix-protecting/anti-inflammatory peptide addresses distinct causes of aging skin.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides are tagged with 'dermal_matrix' in their approved tags, establishing the shared dimension. The mechanisms clearly support complementary action: Palmitoyl Tetrapeptide-7 directly protects extracellular matrix (inhibits MMP-1, stimulates laminin/nidogen, suppresses IL-6/IL-1β inflammatory pathways), while Leuphasyl's primary mechanism targets neuromuscular relaxation and acetylcholine modulation (with secondary in silico evidence for MMP inhibition and TGF-β modulation). The proposed explanation accurately reflects these distinct but non-overlapping pathways—one addressing inflammation and matrix degradation, the other addressing dynamic wrinkle formation through muscle relaxation. The relationship type 'complementary' is justified by the mechanisms showing different routes to skin improvement without direct redundancy.

    Timing Topical; no timing conflict.

    Shares dermal matrix

Safety and side effects

Safety and Side Effects

Safety reviews of palmitoyl oligopeptides (including palmitoyl tetrapeptide-7) concluded that the low use concentrations combined with negative safety test data obviate concerns, and that the ingredient is considered safe in the present practices of use and concentration in cosmetics.

The reviewed safety dataset for palmitoyl oligopeptides included:

  • Chemistry (UV-visible spectral analysis, logP, impurities)
  • Production methods and use-concentration data
  • Acute oral toxicity
  • Ocular irritation
  • Skin irritation/sensitization (animal and human)
  • Genotoxicity

A PT-7 gel demonstrated safety in in vitro testing, and cosmetic compositions containing the peptide were reported to be stable, safe in in vitro and in vivo studies, and to possess preservative properties.

Important Caveats

  • Standalone human evidence is limited. Multiple sources note Pal-GQPR has essentially never been evaluated alone in a controlled human clinical trial; most robust positive results derive from the Matrixyl 3000 two-peptide blend with Pal-GHK, and it is unknown whether Pal-GQPR contributes meaningfully or is overshadowed by the better-studied Pal-GHK. The one cited standalone efficacy study is small (N=17), brief (1 month), and observational.
  • Mechanism is largely proprietary and in vitro. The IL-6 suppression and related mechanistic work is largely from the manufacturer (Sederma) and cell-culture systems; IL-6 suppression has not been confirmed in human skin, and independent peer-reviewed validation is minimal.
  • Single-source claims. Laminin/nidogen stimulation and SASP/inflammaging modulation are reported by only a single source.
  • Data inconsistencies. Sources disagree on molecular weight (~694.9 Da, ~594.78 g/mol, ~687 Da for the same CAS number), and one source uses a conflicting sequence label ('pal-KVK') versus the widely reported GQPR sequence.

Reconstitution and handling

Preparation and Use

Palmitoyl tetrapeptide-7 is a topical cosmetic ingredient rather than an injectable/reconstituted peptide. It is formulated into leave-on products such as creams, gels, and lotions and acts mainly at the site of application, with little systemic absorption.

Typical Concentrations

  • Typical/customary leave-on cosmetic use concentration of the active peptide is below 10 ppm (<0.001%).
  • Cosmetic use concentrations in finished products typically range from 0.001% to 0.01%.
  • In the cited standalone human study, the active was used at 15 ppm for 1 month.
  • In manufacturer clinical testing, the trade-solution blend (Matrixyl 3000, ~3% concentration) was applied twice daily for about two months.

Application

Recommended application is to clean, dry skin, consistently at the same time daily, with evening application often preferred to allow overnight absorption. Peptides generally penetrate the stratum corneum poorly due to high molecular weight, hydrophilic character, and enzymatic degradation; the palmitoyl anchor improves penetration, and nanodelivery systems (e.g., nanoliposomes) have been explored to increase the safety and bioactivity of anti-aging peptides.

Sources

Ordered by evidence quality — the strongest first.

  1. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics(opens in a new tab)
    Tier 1Web · journals.sagepub.com
  2. [PDF] Control Effect of Palmitoyl Teterapeptide-7 Gel to Inflammatory Responses Elicited by PM10 | Semantic Scholar(opens in a new tab)
    Tier 2Web · semanticscholar.org
  3. Anti-aging peptides for advanced skincare: Focus on nanodelivery systems(opens in a new tab)
    Tier 2Web · sciencedirect.com
  4. Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin) | PeptideTrace — PeptideTrace(opens in a new tab)
    Tier 2Web · peptidetrace.com
  5. Solid-phase synthesis of palmitoyl tetrapeptide-7. Adapted ...(opens in a new tab)
    Tier 2Web · researchgate.net
  6. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin - PMC(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  7. Palmitoyl Tetrapeptide-7 Dosing, Need to Know… | Peptide Initiative(opens in a new tab)
    Tier 3Web · peptideinitiative.com
  8. Palmitoyltetrapeptide-7 | SincereSkincare.com(opens in a new tab)
    Tier 3Web · sincereskincare.com
  9. Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics(opens in a new tab)
    Tier 3Web · cir-safety.org
  10. Palmitoyl Tetrapeptide-7: Evidence & Research | Peptidings(opens in a new tab)
    Tier 3Web · peptidings.com · 2026
  11. Palmitoyl Tetrapeptide-7 (Pal-GQPR, Rigin): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 3Web · peptideinsight.com · 2026
  12. Palmitoyl Tetrapeptide-7 | Rigin™ former Palmitoyl Tetrapeptide-3 | Cosmetic Ingredients Guide(opens in a new tab)
    Tier 3Web · ci.guide · 2022
  13. Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts ...(opens in a new tab)
    Tier 3Web · cir-safety.org · 2014
  14. Palmitoyl Tetrapeptide-7 for Anti-Inflammation & Skin Repair(opens in a new tab)
    Tier 4Web · hormonaly.ai
  15. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions(opens in a new tab)
    Tier 4Web · mdpi.com